Clinical Trial Update: A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

This document notes the completion of a Phase 2 trial of AK104, a PD-1/CTLA-4 bispecific antibody, in metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED